Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-1 risk myelofibrosis

Among patients with pre-fibrotic primary myelofibrosis and Dynamic International Prognostic Scoring System low/intermediate-1 risk myelofibrosis receiving ropeginterferon alfa 2b, the clinicohematologic complete response rate was 74% and 67% at 12 and 24 weeks follow-up, respectively. Treatment was also well tolerated, with no discontinuations, safety signals, or treatment-related deaths, according to phase 2 data presented during the 2022 American Society of Hematology Annual Meeting.